GoodRx (NASDAQ:GDRX) Given New $6.00 Price Target at KeyCorp

GoodRx (NASDAQ:GDRX) had its price objective dropped by analysts at KeyCorp from $7.00 to $6.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s target price indicates a potential upside of 39.53% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Barclays lowered their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Citigroup cut their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.43.

GoodRx Stock Performance

NASDAQ:GDRX traded down $0.11 during trading hours on Wednesday, reaching $4.30. 547,586 shares of the company’s stock were exchanged, compared to its average volume of 1,195,033. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -143.33, a P/E/G ratio of 3.43 and a beta of 1.27. The company has a 50-day moving average of $4.83 and a 200 day moving average of $6.62.

Institutional Investors Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently modified their holdings of GDRX. ClariVest Asset Management LLC grew its holdings in shares of GoodRx by 27.4% in the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after acquiring an additional 42,097 shares during the period. American Century Companies Inc. acquired a new stake in GoodRx in the second quarter valued at $18,183,000. Cornercap Investment Counsel Inc. increased its position in shares of GoodRx by 1.7% in the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after buying an additional 1,266 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of GoodRx during the 2nd quarter worth $43,000. Finally, XTX Topco Ltd boosted its position in shares of GoodRx by 42.4% in the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after buying an additional 8,801 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.